GALECTO BIOTECH ApS: Financial statements 2023
CVR: 34878366
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
GALECTO BIOTECH ApS (CVR 34878366) has filed annual accounts for 2023. In 2023, the company reported a gross profit of EUR 15,256,504 and a net result of EUR 849,392 compared with EUR 818,741 the year before. That is an increase of 24.2% compared with the year before. Equity in the 2023 report amounted to EUR 8,243,407. The solvency ratio was 77.3%. The company had 29 employees in the financial year.
- Gross Profit
- EUR 15,256,504
- Profit/Loss
- EUR 849,392
- Equity
- EUR 8,243,407
- Total Assets
- EUR 10,668,440
- Employees
- 29
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 15.3 mio. EUR | 849 t. EUR | 8.2 mio. EUR | 29 |
| 2022 | - | 12.3 mio. EUR | 819 t. EUR | 7.4 mio. EUR | 36 |
| 2021 | - | 9.4 mio. EUR | 765 t. EUR | 3.7 mio. EUR | 29 |
| 2020 | - | 4.9 mio. EUR | 214 t. EUR | 2.9 mio. EUR | 16 |
| 2019 | - | 2.4 mio. EUR | 324 t. EUR | 2.7 mio. EUR | 11 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of September 27, 2023, Hans Thalsgård Schambye has joined the board of directors of GALECTO BIOTECH ApS.
As of September 27, 2023, Anders Hjelholt Pedersen has left the board of directors of GALECTO BIOTECH ApS.
As of September 27, 2023, Bertil Erik Lindmark has left the board of directors of GALECTO BIOTECH ApS.
As of September 26, 2023, Hans Thalsgård Schambye has left the board of directors of GALECTO BIOTECH ApS.
GALECTO BIOTECH ApS has published its annual report for 2022. Gross profit came to DKK 12,287,141, and the net result was DKK 818,741.
About GALECTO BIOTECH ApS
GALECTO BIOTECH ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Garrett Michael Winslow. The company is owned by Galecto Biotech AB. The company has 3 employees (2018). In 2025, the company reported a gross profit of EUR 1,039,275 and a net result of EUR -709,079 compared with EUR 310,297 the year before. Equity in the 2025 report amounted to EUR 7,844,625.